# Quantum X Labs Inc.: financial statements, quarterly

QXL · Nasdaq · CIK 797542 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qxl.md) · [Financials](/companies/qxl/financials.md) · [Filings](/companies/qxl/filings.md) · [Insiders](/companies/qxl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qxl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.7](/filings/0001493152-24-046797.md) | [15.9 d](/filings/0001493152-25-011100.md) | [10.0](/filings/0001641172-25-010059.md) | [7.3](/filings/0001641172-25-024831.md) | [6.3](/filings/0001493152-25-023501.md) | [3.3 d](/filings/0001493152-25-011100.md) | [2.7](/filings/0001641172-25-010059.md) | [2.3](/filings/0001641172-25-024831.md) | [2.7](/filings/0001493152-25-023501.md) | not reported | not reported | [0.3](/filings/0001493152-26-037811.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.7](/filings/0001493152-24-046797.md) | [0.7 d](/filings/0001493152-25-011100.md) | [0.7](/filings/0001641172-25-010059.md) | [0.5](/filings/0001641172-25-024831.md) | [0.3](/filings/0001493152-25-023501.md) | [(0.8) d](/filings/0001493152-26-013205.md) | [0.0](/filings/0001493152-26-023169.md) | [0.0](/filings/0001493152-26-037811.md) | [0.1](/filings/0001493152-25-023501.md) | [(0.3) d](/filings/0001493152-26-013205.md) | not reported | [0.2](/filings/0001493152-26-037811.md) |
| Operating income | $m | [(1.7)](/filings/0001493152-24-046797.md) | [(6.0) d](/filings/0001493152-25-011100.md) | [(1.0)](/filings/0001641172-25-010059.md) | [(5.5)](/filings/0001641172-25-024831.md) | [(0.9)](/filings/0001493152-25-023501.md) | [6.6 d](/filings/0001493152-26-013205.md) | [(0.1)](/filings/0001493152-26-023169.md) | [(1.0)](/filings/0001493152-26-037811.md) | [(3.6)](/filings/0001493152-25-023501.md) | [7.3 d](/filings/0001493152-26-013205.md) | [(0.6)](/filings/0001493152-26-023169.md) | [(1.4)](/filings/0001493152-26-037811.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.1)](/filings/0001493152-24-046797.md) | [(0.1) d](/filings/0001493152-25-011100.md) | [0.0](/filings/0001641172-25-010059.md) | [(0.0)](/filings/0001641172-25-024831.md) | [(0.1)](/filings/0001493152-25-023501.md) | [0.2 d](/filings/0001493152-26-013205.md) | [0.0](/filings/0001493152-26-023169.md) | [(0.1)](/filings/0001493152-26-037811.md) | [(0.3)](/filings/0001493152-25-023501.md) | [0.5 d](/filings/0001493152-26-013205.md) | [(0.0)](/filings/0001493152-26-023169.md) | [(0.1)](/filings/0001493152-26-037811.md) |
| Net income | $m | [(1.5)](/filings/0001493152-24-046797.md) | [(5.3) d](/filings/0001493152-25-011100.md) | [(1.0)](/filings/0001641172-25-010059.md) | [(7.2)](/filings/0001641172-25-024831.md) | [(0.6)](/filings/0001493152-25-023501.md) | [(3.3) d](/filings/0001493152-26-013205.md) | [(3.7)](/filings/0001493152-26-023169.md) | [(11.7)](/filings/0001493152-26-037811.md) | [(3.4)](/filings/0001493152-25-023501.md) | [(0.6) d](/filings/0001493152-26-013205.md) | [(0.6)](/filings/0001493152-26-023169.md) | [2.5](/filings/0001493152-26-037811.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001493152-24-046797.md) | not reported | [0.27](/filings/0001641172-25-010059.md) | [1.91](/filings/0001641172-25-024831.md) | [0.12](/filings/0001493152-25-023501.md) | not reported | [0.68](/filings/0001493152-26-023169.md) | [(1.61)](/filings/0001493152-26-037811.md) | [0.32](/filings/0001493152-25-023501.md) | not reported | [0.05](/filings/0001493152-26-023169.md) | [0.12](/filings/0001493152-26-037811.md) |
| Basic EPS | $ per share | [(0.10)](/filings/0001493152-24-046797.md) | not reported | [0.27](/filings/0001641172-25-010059.md) | [1.91](/filings/0001641172-25-024831.md) | [0.12](/filings/0001493152-25-023501.md) | not reported | [0.68](/filings/0001493152-26-023169.md) | [(1.61)](/filings/0001493152-26-037811.md) | [0.32](/filings/0001493152-25-023501.md) | not reported | [0.05](/filings/0001493152-26-023169.md) | [0.17](/filings/0001493152-26-037811.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.6](/filings/0001493152-23-041065.md) | [1.8](/filings/0001493152-25-011100.md) | [1.3](/filings/0001493152-24-020755.md) | [0.6](/filings/0001493152-24-032365.md) | [1.4](/filings/0001493152-24-046797.md) | [0.0](/filings/0001493152-26-013205.md) | [0.2](/filings/0001641172-25-010059.md) | [2.0](/filings/0001641172-25-024831.md) | [2.2](/filings/0001493152-25-023501.md) | [1.0](/filings/0001493152-26-037811.md) | [1.8](/filings/0001493152-26-023169.md) | [2.4](/filings/0001493152-26-037811.md) |
| Current assets | $m | [18.8](/filings/0001493152-23-041065.md) | [17.8](/filings/0001493152-25-011100.md) | [12.8](/filings/0001493152-24-020755.md) | [11.4](/filings/0001493152-24-032365.md) | [12.9](/filings/0001493152-24-046797.md) | [7.8](/filings/0001493152-26-013205.md) | [6.5](/filings/0001641172-25-010059.md) | [4.1](/filings/0001641172-25-024831.md) | [4.1](/filings/0001493152-25-023501.md) | [1.7](/filings/0001493152-26-037811.md) | [2.9](/filings/0001493152-26-023169.md) | [3.5](/filings/0001493152-26-037811.md) |
| Total assets | $m | [50.2](/filings/0001493152-23-041065.md) | [43.3](/filings/0001493152-25-011100.md) | [37.5](/filings/0001493152-24-020755.md) | [30.0](/filings/0001493152-24-032365.md) | [30.8](/filings/0001493152-24-046797.md) | [22.0](/filings/0001493152-26-013205.md) | [26.4](/filings/0001641172-25-010059.md) | [20.1](/filings/0001641172-25-024831.md) | [16.9](/filings/0001493152-25-023501.md) | [10.8](/filings/0001493152-26-037811.md) | [27.7](/filings/0001493152-26-023169.md) | [31.2](/filings/0001493152-26-037811.md) |
| Current liabilities | $m | [20.6](/filings/0001493152-23-041065.md) | [19.8](/filings/0001493152-25-011100.md) | [15.9](/filings/0001493152-24-020755.md) | [15.5](/filings/0001493152-24-032365.md) | [16.9](/filings/0001493152-24-046797.md) | [12.9](/filings/0001493152-26-013205.md) | [15.4](/filings/0001641172-25-010059.md) | [12.7](/filings/0001641172-25-024831.md) | [8.6](/filings/0001493152-25-023501.md) | [4.1](/filings/0001493152-26-037811.md) | [4.2](/filings/0001493152-26-023169.md) | [4.0](/filings/0001493152-26-037811.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [2.7](/filings/0001493152-23-041065.md) | [3.1](/filings/0001493152-25-011100.md) | [2.4](/filings/0001493152-24-020755.md) | [1.7](/filings/0001493152-24-032365.md) | [1.1](/filings/0001493152-24-046797.md) | [0.5](/filings/0001493152-26-013205.md) | not reported | not reported | [0.8](/filings/0001493152-25-023501.md) | [0.6](/filings/0001493152-26-037811.md) | [0.4](/filings/0001493152-26-023169.md) | [0.2](/filings/0001493152-26-037811.md) |
| Current portion of debt | $m | [1.9](/filings/0001493152-23-041065.md) | [1.4](/filings/0001493152-25-011100.md) | [2.1](/filings/0001493152-24-020755.md) | [2.1](/filings/0001493152-24-032365.md) | [2.5](/filings/0001493152-24-046797.md) | [3.1](/filings/0001493152-26-013205.md) | [2.9](/filings/0001641172-25-010059.md) | [2.2](/filings/0001641172-25-024831.md) | [0.8](/filings/0001493152-25-023501.md) | [0.8](/filings/0001493152-26-037811.md) | [0.8](/filings/0001493152-26-023169.md) | [0.8](/filings/0001493152-26-037811.md) |
| Short-term borrowings | $m | [6.0](/filings/0001493152-23-041065.md) | [5.0](/filings/0001493152-25-011100.md) | [4.4](/filings/0001493152-24-020755.md) | [2.4](/filings/0001493152-24-032365.md) | [2.6](/filings/0001493152-24-046797.md) | [1.5](/filings/0001493152-26-013205.md) | [2.9](/filings/0001641172-25-010059.md) | [3.2](/filings/0001641172-25-024831.md) | [1.3](/filings/0001493152-25-023501.md) | [0.3](/filings/0001493152-26-037811.md) | [0.3](/filings/0001493152-26-023169.md) | [0.3](/filings/0001493152-26-037811.md) |
| Shareholders' equity | $m | [20.1](/filings/0001493152-23-041065.md) | [14.8](/filings/0001493152-25-011100.md) | [13.8](/filings/0001493152-24-020755.md) | [7.1](/filings/0001493152-24-032365.md) | [9.0](/filings/0001493152-24-046797.md) | [5.8](/filings/0001493152-26-013205.md) | [7.3](/filings/0001641172-25-010059.md) | [4.5](/filings/0001641172-25-024831.md) | [5.6](/filings/0001493152-25-023501.md) | [5.0](/filings/0001493152-26-037811.md) | [21.6](/filings/0001493152-26-023169.md) | [25.8](/filings/0001493152-26-037811.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(276)](/filings/0001493152-24-046797.md) | [195 d](/filings/0001493152-25-011100.md) | [107](/filings/0001641172-25-010059.md) | [1,349](/filings/0001641172-25-024831.md) | [534](/filings/0001493152-25-023501.md) | [(447) d](/filings/0001493152-25-011100.md) | [(409)](/filings/0001641172-25-010059.md) | [(427)](/filings/0001641172-25-024831.md) | [(1,715)](/filings/0001493152-25-023501.md) | [(218) d](/filings/0001493152-26-013205.md) | [(604)](/filings/0001493152-26-023169.md) | [(1,062)](/filings/0001493152-26-037811.md) |
| Capital expenditure | $k | [3.0](/filings/0001493152-24-046797.md) | [3.0 d](/filings/0001493152-25-011100.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [186](/filings/0001493152-26-037811.md) |
| Dividends paid | $k | [0.0 d](/filings/0001493152-24-046797.md) | [0.0 d](/filings/0001493152-25-011100.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.8](/filings/0001493152-23-041065.md) | [14.8](/filings/0001493152-24-020755.md) | [14.8](/filings/0001493152-24-032365.md) | [14.9](/filings/0001493152-24-046797.md) | [3.7](/filings/0001641172-25-010059.md) | [3.8](/filings/0001641172-25-024831.md) | [5.1](/filings/0001493152-25-023501.md) | [5.4](/filings/0001493152-26-023169.md) | [7.2](/filings/0001493152-26-037811.md) | [10.5](/filings/0001493152-25-023501.md) | [11.5](/filings/0001493152-26-023169.md) | [20.1](/filings/0001493152-26-037811.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,567,826 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037811.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.